title: Deleterious myocardial consequences induced by intermittent hypoxia are reversed by erythropoietin.
abstract: The aim of this work was to investigate the effects of different recombinant human erythropoietin (rhEPO) doses on the infarction development and if rhEPO could protect against the deleterious consequences induced by a previous intermittent hypoxia (IH, FiO(2) 5%, 4h). First, isolated rat hearts were submitted to an ischemia-reperfusion. rhEPO was infused before or after ischemia, at different doses. Secondly, rats were exposed to of IH. Twenty-four hours later, hearts underwent the ischemia-reperfusion protocol. For some hearts, 5Uml(-1) rhEPO was infused as previously. We observed that rhEPO has a dose-dependant effect on infarct size since it was significantly reduced by rhEPO infusions before or after ischemia. We also showed that 4h of IH induced a higher sensitivity to the infarction which was prevented by rhEPO. In conclusion, rhEPO administration before or after ischemia can protect isolated rat myocardium in a dose dependent manner and efficiently prevents the higher sensitivity to the infarction induced by previous intermittent hypoxia.
authors.affiliation: Laboratoire HP2, Hypoxie Physio-Pathologie Respiratoire et Cardiovasculaire, EA 3745, ERI 0017, Institut Jean Roget, BP 170, 38042 Grenoble Cedex 9, France.
authors.forename: A
authors.initials: A
authors.lastname: Ramond
authors.forename: C
authors.initials: C
authors.lastname: Ribuot
authors.forename: P
authors.initials: P
authors.lastname: Lévy
authors.forename: M
authors.initials: M
authors.lastname: Joyeux-Faure
mesh_terms: D000818:Animals; D003326:Coronary Circulation / Q000187:drug effects / Q000502:physiology; D004921:Erythropoietin / Q000008:administration & dosage / Q000627:therapeutic use*; D006331:Heart Diseases / Q000209:etiology / Q000473:pathology* / Q000517:prevention & control*; D006339:Heart Rate / Q000187:drug effects / Q000502:physiology; D000860:Hypoxia / Q000150:complications* / Q000503:physiopathology*; D066298:In Vitro Techniques; D008297:Male; D009203:Myocardial Infarction / Q000188:drug therapy / Q000209:etiology / Q000473:pathology; D017202:Myocardial Ischemia / Q000188:drug therapy / Q000473:pathology; D015428:Myocardial Reperfusion Injury / Q000188:drug therapy / Q000473:pathology; D009206:Myocardium / Q000473:pathology*; D051381:Rats; D017208:Rats, Wistar; D011994:Recombinant Proteins; D016277:Ventricular Function, Left / Q000187:drug effects / Q000502:physiology
chemical_list: D011994:Recombinant Proteins; D004921:Erythropoietin